The study, which was conducted by researchers from Tulane, Central South University in China, the University of Oklahoma Health Sciences Center, Temple University, and Florida State University, was designed to test whether AI could be a tool to help pathologists keep pace with the rising demand for their services.
Nowadays, Artificial Intelligence (AI) is deployed more and more to predict life-threatening disease. But there remains a big challenge in getting the Machine Learning (ML) algorithms precise enough.
Variation is a cardinal feature of biology, the driver of diversity, and the engine of evolution, but it has a dark side. Alterations in DNA sequences and the resulting proteins that build our cells can sometimes lead to profound disruptions in physiologic function and cause disease.
The computer modelling tool will predict novel sites of binding for potential drugs that are more selective, leading to more effective drug targeting, increasing therapeutic efficacy and reducing side effects.